Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
8.31
+0.32 (4.01%)
At close: Jun 12, 2026, 4:00 PM EDT
8.47
+0.16 (1.93%)
After-hours: Jun 12, 2026, 7:55 PM EDT
Xilio Therapeutics Market Cap
Xilio Therapeutics has a market cap or net worth of $49.72 million as of June 12, 2026. Its market cap has decreased by -0.39% in one year.
Market Cap
49.72M
Enterprise Value
-93.98M
1-Year Change
-0.39%
Ranking
Category
Stock Price
$8.31
Market Cap Chart
Since the IPO on October 22, 2021, Xilio Therapeutics's market cap has decreased from $426.71M to $49.72M, a decrease of -88.35%. That is a compound annual growth rate of -37.07%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 12, 2026 | 49.72M | 47.92% |
| Dec 31, 2025 | 33.61M | -19.94% |
| Dec 31, 2024 | 41.98M | 177.26% |
| Dec 29, 2023 | 15.14M | -79.46% |
| Dec 30, 2022 | 73.73M | -83.14% |
| Dec 31, 2021 | 437.33M | 2.49% |
| Oct 22, 2021 | 426.71M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Edesa Biotech | 50.20M |
| Mereo BioPharma Group | 49.77M |
| Tevogen Bio Holdings | 48.87M |
| Immutep | 48.45M |
| Actuate Therapeutics | 47.61M |
| Radiopharm Theranostics | 47.10M |
| Metagenomi Therapeutics | 46.87M |
| aTyr Pharma | 46.61M |